Market Overview

UPDATE: Deutsche Bank Upgrades Johnson & Johnson to Buy on Improving Trends

Share:
Related JNJ
3 Most Likely Suitors For Colgate-Palmolive, In Jefferies' View
Johnson & Johnson's Sales Slump Has Played Itself Out, Could Reaccelerate This Year
Multiple-Plaintiff Trial Involving J&J Set to Start (GuruFocus)

Deutsche Bank raised its rating on Johnson & Johnson (NYSE: JNJ) from Hold to Buy and increased its price target from $75 to $82.

Deutsche Bank commented, "For the past several years, JNJ has weathered through patent expirations, a general slowdown in utilization trends, and challenges with its OTC businesses. As we look ahead to 2013, we believe JNJ will see improving trends. We expect recent and new drugs to continue to drive pharma sales. A slight improvement in utilization and new products should benefit MD&D. For Consumer, J&J should continue to work through the McNeil Consent Decree and return products to market. Given these improving trends and the benefits of diversification, we believe JNJ deserves a premium to its peers."

Johnson & Johnson closed at $70.74 on Thursday.

Latest Ratings for JNJ

DateFirmActionFromTo
May 2017JP MorganUpgradesNeutralOverweight
Jan 2017Wells FargoDowngradesOutperformMarket Perform
Nov 2016BarclaysDowngradesOverweightEqual-Weight

View More Analyst Ratings for JNJ
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (JNJ)

View Comments and Join the Discussion!